ClinicalTrials.gov
public full text
Public Domain
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
This proof of concept trial aims to assess whether the combination of IRE with Nivolumab is safe and effective to treat metastatic pancreatic cancer, based on the available preliminary evidence that IRE is able to cause a systemic anti-tumor immune response (i.e. abscopal effect), which may enhance the effect of subsequent Nivolumab treatment. In addition, the trial aims to clarify the systemic effects of IRE over time and thereby to provide more insight in the mechanism of work of the technique.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer#886269
- Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer#1060462
- A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer#1161409
- Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma#912488
- Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer#1173589
Record · ID 840375
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive